Selinexor is a Small Molecule owned by Karyopharm Therapeutics, and is involved in 96 clinical trials, of which 39 were completed, 50 are ongoing, and 7 are planned.
Selinexor is a selective inhibitor of nuclear export. It inhibits CRM1 (chromosome region maintenance 1 protein, exportin 1 or XPO1). CRM1, the major export factor for proteins from the nucleus to the cytoplasm, is over-expressed in a variety of cancer cell types. The export protein CRM1 is required for the nuclear export of a wide variety of cancer-related cargo proteins including p53 (a tumor suppressor protein), c-Abl, (a protein tyrosine kinase), and FOXO-3A (this protein is likely to function as a trigger for apoptosis). CRM1 recognizes its cargo proteins through their leucine-rich nuclear export sequence. The CRM1-cargo complex is then actively transported across the nuclear pore complex to the cytoplasm where the cargo is released after RanGAP-catalyzed GTP hydrolysis. RanGAP is a protein involved in the transport of other proteins from the cytosol to the nucleus in eukaryotic cells.
The revenue for Selinexor is expected to reach a total of $4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Selinexor NPV Report.
Selinexor was originated by Rega Institute for Medical Research and Karyopharm Therapeutics and is currently owned by Karyopharm Therapeutics. Antengene is the other company associated in development or marketing of Selinexor.
Selinexor (Xpovio, Nexpovio) is an antineoplastic agent. It is formulated as film coated tablets for oral route of administration. Xpovio in combination with dexamethasone is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. Xpovio is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy. Xpovio in combination with bortezomib and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Selinexor (KPT-330) is under development for the treatment of light chain amyloidosis, anaplastic astrocytoma, diffuse intrinsic pontine glioma (DIPG), high-grade glioma (HGG), newly diagnosed advanced hepatocellular carcinoma, metastatic urothelial carcinoma, relapsed or refractory peripheral T cell lymphoma and natural killer T cell lymphomas, relapsed/refractory indolent non-Hodgkin lymphoma (R/R iHNL), malignant peripheral nerve sheath tumor (MPNST), leiomyosarcoma, endometrial stromal sarcoma, ovarian carcinoma, endometrial carcinoma, fallopian tube cancer, metastatic triple negative breast cancer, thymoma, non-small cell lung cancer, cervical carcinoma, non-Hodgkin lymphoma, melanoma, colon cancer, gastroenteropancreatic tumors, prolymphocytic leukemia, small lymphocytic lymphoma, recurrent glioblastoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia (CLL), relapsed/refractory multiple myeloma (MM), relapsed and refractory acute myelogenous leukemia (AML), diffuse large B-cell lymphoma, chondrosarcoma, synovial sarcoma, liposarcoma, leiomyosarcoma, blast-crisis chronic myelogenous leukemia (bc-CML), relapsed and refractory acute lymphoblastic leukemia, rectal cancer, lung cancer, gynecological cancer, Penta-refractory multiple myeloma, recurrent/refractory high-grade gliomas, myelofibrosis, primary myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Ewing sarcoma and myelodysplastic syndrome, gastrointestinal stromal tumor (GIST), non-small cell lung cancer and recurrent glioma. The drug candidate is administered orally as a tablet and topically as a gel. It is a SINE compound that acts by targeting CRM1 (chromosome region maintenance 1 protein, exportin 1 or XPO1).
It was also under development for the treatment of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), refractory or relapsed Richter's transformation, metastatic castrate-resistant prostate cancer, advanced squamous cell carcinoma of head and neck, lung cancer and esophageal cancer, relapsed/refractory cutaneous T cell lymphoma, relapsed small cell lung cancer, rectal adenocarcinoma, gastric cancer, metastatic colorectal cancer and diabetic foot ulcers.
It was also under development for the treatment of recurrent glioblastoma multiforme.
Karyopharm Therapeutics Overview
Karyopharm Therapeutics (Karyopharm Therapeutic) discovers and develops novel drugs for the treatment of cancer and other diseases. The company’s core technology harnesses the inhibition of nuclear export as a mechanism to treat patients suffering from cancer. Karyopharm’s lead product, Xpovio, is recommended for the treatment of multiple myeloma, and relapsed or refractory diffuse large B-cell lymphoma. Its pipeline drug candidates include selinexor, eltanexor, verdinexor, and KPT-9274. Karyopharm’s drug candidates are indicated for the treatment of various hematological and solid tumor malignancies including multiple myeloma, diffuse large B-cell lymphoma, liposarcoma, glioblastoma and endometrial cancer. The company has operations in the US, Israel and Germany. Karyopharm is headquartered in Newton, Massachusetts, the US.
The company reported revenues of (US Dollars) US$209.8 million for the fiscal year ended December 2021 (FY2021), an increase of 94.1% over FY2020. The operating loss of the company was US$98.3 million in FY2021, compared to an operating loss of US$171.9 million in FY2020. The net loss of the company was US$124.1 million in FY2021, compared to a net loss of US$196.3 million in FY2020. The company reported revenues of US$36.2 million for the third quarter ended September 2022, a decrease of 8.9% over the previous quarter.
Quick View – Selinexor
|Highest Development Stage|